• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

by | Mar 4, 2024 | Myeloma News

Source: Pharmacy Times articles Experts discuss challenges related to the implementation of bispecific antibodies for the treatment of multiple myeloma and emphasize the critical role of interinstitutional collaboration in developing bispecific antibody programs. Read...

A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models

by | Mar 1, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up

by | Feb 28, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

FDA Withdraws Approval of Melphalan Flufenamide for the Treatment of Multiple Myeloma

by | Feb 26, 2024 | Myeloma News

Source: Pharmacy Times articles The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone. Read More

Ciltacabtagene-Autoleucel Recommended for Approval to Treat Relapsed/Refractory Multiple Myeloma

by | Feb 26, 2024 | Myeloma News

Source: Pharmacy Times articles The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma. Read More

Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

by | Feb 26, 2024 | Myeloma News

Source: Pharmacy Times articles Experts discuss their institution’s implementation of step-up dosing for bispecific antibodies and share their best practices. Read More
« Older Entries
Next Entries »

Recent Content

  • CAR-T cell therapy in Multiple Myeloma: current status and future challenges
  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT